Equities Analysts Set Expectations for TVTX Q2 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for Travere Therapeutics in a report issued on Wednesday, June 11th. HC Wainwright analyst E. Arce forecasts that the company will post earnings of ($0.38) per share for the quarter. HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Travere Therapeutics' Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($1.44) EPS and FY2026 earnings at $0.42 EPS.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,179.73% and a negative net margin of 82.88%. The company had revenue of $81.73 million during the quarter, compared to analyst estimates of $77.44 million. During the same quarter last year, the business posted ($1.76) earnings per share. The firm's revenue was up 83.3% on a year-over-year basis.

TVTX has been the topic of several other research reports. Guggenheim reissued a "buy" rating and issued a $47.00 target price on shares of Travere Therapeutics in a research note on Monday, April 14th. Citigroup cut their price target on shares of Travere Therapeutics from $35.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, June 11th. Scotiabank reissued an "outperform" rating on shares of Travere Therapeutics in a research report on Friday, April 11th. Canaccord Genuity Group boosted their target price on Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Finally, Bank of America increased their price target on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $32.14.

Travere Therapeutics Trading Up 2.3%

Shares of Travere Therapeutics stock traded up $0.32 on Monday, reaching $14.41. The company had a trading volume of 1,951,900 shares, compared to its average volume of 1,623,838. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -5.13 and a beta of 0.75. The company has a debt-to-equity ratio of 9.46, a current ratio of 2.05 and a quick ratio of 2.03. The firm's 50-day moving average price is $16.88 and its two-hundred day moving average price is $18.44. Travere Therapeutics has a 1 year low of $6.80 and a 1 year high of $25.29.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors have recently bought and sold shares of the company. Armistice Capital LLC lifted its holdings in shares of Travere Therapeutics by 20.6% during the 1st quarter. Armistice Capital LLC now owns 8,872,000 shares of the company's stock valued at $158,986,000 after purchasing an additional 1,514,000 shares during the last quarter. Rock Springs Capital Management LP increased its position in Travere Therapeutics by 6.2% during the 4th quarter. Rock Springs Capital Management LP now owns 4,973,649 shares of the company's stock valued at $86,641,000 after buying an additional 289,173 shares in the last quarter. Driehaus Capital Management LLC increased its position in Travere Therapeutics by 24.8% during the 1st quarter. Driehaus Capital Management LLC now owns 2,767,693 shares of the company's stock valued at $49,597,000 after buying an additional 549,718 shares in the last quarter. Renaissance Technologies LLC raised its stake in Travere Therapeutics by 28.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company's stock valued at $41,974,000 after buying an additional 534,500 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in Travere Therapeutics by 479.9% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,184,898 shares of the company's stock worth $39,153,000 after acquiring an additional 1,808,098 shares in the last quarter.

Insider Transactions at Travere Therapeutics

In other news, insider Peter Heerma sold 1,771 shares of Travere Therapeutics stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,279.55. Following the transaction, the insider now owns 128,215 shares of the company's stock, valued at $2,698,925.75. The trade was a 1.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christopher R. Cline sold 1,784 shares of the business's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $37,553.20. Following the transaction, the chief financial officer now owns 93,126 shares of the company's stock, valued at approximately $1,960,302.30. This trade represents a 1.88% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,527 shares of company stock valued at $473,814. Company insiders own 4.19% of the company's stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.